PHVS Study Shows Deucrictibant Cuts HAE Attack Relief Time to Just 1.28 Hours: Phase 3 Results Impress
Market Chameleon (Wed, 3-Dec 10:29 AM)
Pharvaris Reports Rapid Symptom Relief and Broad Efficacy for Deucrictibant in Landmark Phase 3 HAE Study
Market Chameleon (Wed, 3-Dec 7:29 AM)
